Protara Therapeutics, Inc. (TARA) Dividend History

Company News

• Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

  Protara Therapeutics announced positive interim results from its ongoing Phase 2 ADVANCED-2 trial of TARA-002, its investigational cell-based therapy, in patients with high-risk non-muscle invasive bladder cancer (NMIBC). The results showed high complete response rates and a favorable safety profile.

  GlobeNewswire Inc.
• Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday

  Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Susquehanna raised the price target for Occidental Petroleum Corporation (NYSE:OXY) from $70 to $81. Susquehanna analyst Biju Perincheril maintained a Positive rating. Occidental Petroleum shares rose 0.9% to close at $66.63 on Friday. See how other analysts view this stock. Keybanc boosted the price target for Alphabet Inc. (NASDAQ:GOOGL) from $165 to $175. Keybanc analyst Justin Patterson maintained an Overweight rating. Alphabet shares fell 1.2% to close at $154.09 on Friday. See how other analysts view this stock. Chardan Capital increased Ocugen, Inc. (NASDAQ:OCGN) price target from $4 to $5. Chardan Capital analyst Daniil Gataulin maintained a Buy rating. Ocugen shares ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: AA BYND COP FIVN GOOGL META OCGN OXY
• Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now

  Protara Therapeutics (TARA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

  Zacks Investment Research